Conceptus (NASDAQ: CPTS)‘s stock had its “buy” rating reaffirmed by GARP Research in a research note issued on Monday.
A number of other analysts have also recently weighed in on CPTS. Analysts at Piper Jaffray (NYSE: PJC) upgraded shares of Conceptus from a “neutral” rating to an “overweight” rating in a research note to investors on Monday. Finally, analysts at Zacks upgraded shares of Conceptus from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, February 22nd.
Conceptus opened at 18.77 on Monday. Conceptus has a 52-week low of $9.68 and a 52-week high of $20.20. The company’s market cap is $587.6 million.
The company last announced its quarterly results on Thursday, April 26th. It reported ($0.09) earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.13) EPS by $0.04. The company’s quarterly revenue was up 9.0% on a year-over-year basis. Analysts expect that Conceptus will post $0.04 EPS next quarter.
Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women.